Effect of delapril/manidipine vs olmesartan/hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients

Internal Medicine

Volumn 47, Issue 5, 2008, Pages 361-366

  Fogari, Roberto ^a   Derosa, Giuseppe ^a   Zoppi, Annalisa ^a   Lazzari, Pierangelo ^a   Corradi, Luca ^a   Preti, Paola ^a   Mugellini, Amedeo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Delapril manidipine; Fibrinogen; Hypertension; Insulin resistance; Obesity

Indexed keywords

DELAPRIL; FIBRINOGEN; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; MANIDIPINE; OLMESARTAN; PLACEBO; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAZOLE DERIVATIVE; INDAN DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OBESITY; OPEN STUDY; PARALLEL DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; GLUCOSE CLAMP TECHNIQUE; MIDDLE AGED;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DRUG COMBINATIONS; FEMALE; FIBRINOGEN; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; INDANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; TETRAZOLES;

EID: 40949124784     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0449     Document Type: Article

References (48)

1. Mokdad AH, Ford Es, Bowman BA, et al. Prevalence of obesity, diabetes and obesity related health risk factors. JAMA 289: 76-79, 2003.
2. Aneja A, El-Atat F, Mc Farlane SI, Sowers JR. Hypertension and obesity. Recent Prog Horm Res 59: 169-205, 2004.
3. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathetic nervous system. N Engl J Med 334: 374-381, 1996.
4. Landin Y, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 227: 273-278, 1990.
5. Jeng JR, Sheu WM, Jeng CY, Huang SH, Shieh SM. Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 9: 484-490, 1996.
6. Lijnen HR, Collen D. Endothelium in homeostasis and thrombosis. Prog Cardiovasc Dis 39: 343-350, 1997.
7. Tomiyama H, Kimura Y, Mitsushashi H, et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 31: 321-327, 1998.
8. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 289: 2560-2572, 2003.
9. ESH-ESC Guidelines Committee. 2003 Guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053, 2003.
10. Dentali F, Sharma AM, Douketis JD. Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Rep 7: 330-336, 2005.
11. Doggrell SA. Clinical evidence for drug treatments in obesity-associated hypertensive patients - a discussion paper. Methods Find Exp Clin Pharmacol 27: 119-125, 2005.
12. Wenzel UO, Krebs C. Treatment of arterial hypertension in obese patients. Contrib Nephrol 151: 230-242, 2006.
13. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnel CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 36: 594-599, 2000.
14. Lithell H, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 15 (Suppl 5): S46-S52, 1990.
15. Torlone E, Britta A, Rambotti AM. Improved insulin action and glycemic control after longterm angiotensin converting enzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care 16: 1347-1355, 1993.
16. Falkner B, Canessa M, Anzalone D. Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertension. Am J Hypertens 8: 454-460, 1995.
17. Fogari R, Zoppi A, Malamani GD, Marasi G, Vanasia A, Villa G. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 39: 471-476, 1995.
18. Fogari R, Zoppi A, Corradi L, Lazzari P, Mugellini A, Lusardi P. Comparative effect of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 46: 467-471, 1998.
19. Fogari R, Zoppi A, Lazzari P, et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 32: 616-620, 1998.
20. Iimura O, Shimamoto K, Matsuda K, et al. Effects of angiotensin receptor antagonist andangiotensin converting enzyme inhibitor on insulin sensitivity and fructose fed hypertensive rats and essential hypertensives. Am J Hypertens 8: 353-357, 1995.
21. Moan A, Hoieggen A, Nordby G, Eide IK, Kjelsen SE. Effects of losartan on insulin sensitivity in severe hypertension:connections through sympathetic nervous system activity. J Hum Hypertens 9 (Suppl 5): S45-S50, 1995.
22. Fogari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivita in hypertensive obese patients. Hypertens Res 28: 209-214, 2005.
23. Trost BN, Weidman P. Effects of calcium antagonists on glucose homeostasis and serum lipids in non-diabetic and diabetic subjects: a review. J Hypertens 5: S81-S104, 1987.
24. Beeer NA, Jakubowicz DJ, Beer RM, Arocha IR, Nestler JE. Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 76: 178-183, 1993.
25. Ueshiba H, Miyachi Y. Effects of long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern Med 43: 561-565, 2004.
26. De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 237: 214-223, 1979.
27. Clauss A. Rapid physiological coagulation method for the determination of fibrinogen. Acta Haematol 17: 237-246, 1957.
28. Asfaha S, Padwal R. Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice. Curr Hypertens Rep 7: 314-322, 2005.
29. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the rennin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23: 463-473, 2005.
30. Ostergren J. Renin-angiotensin system blockade in the prevention of diabetes. Diabetes Res Clin Pract 73(Suppl 3): S13-S21, 2007.
31. Tomiyama H, Kushiro T, Abeta H, et al. Kinins contribute to the improvement of insulin sensitivita during treatment with angiotensin converting enzyme inhibitor. Hypertension 23: 450-455, 1994.
32. Rett K, Wicklay R, Diewtze GJ. Metabolic effects of kinins: historical and recent developments. J Cardiovasc Pharmacol 15: 1620-1628, 1990.
33. Kon V, Jabs K. Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 13: 291-297, 2004.
34. Baron AD, Brechtel GB, Wallace P, Edelman SV. Rates and tissue sites of non-insulin and insulin-mediated glucose uptake in humans. Am J Physiol 255: E769-E774, 1988.
35. Draznin B, Sussman KE, Eckel RA, Kao M, Yost T, Sherman MA. Possible role of cytosolic free calcium in mediating insulin resistance in obesity and hyperinsulinemia. J Clin Invest 82: 1848-1852, 1988.
36. Koenig W, Sund M, Ernst E, et al. Effects of felodipine ER and hydrochlorothiazide on bloodrheology in essential hypertension-a randomized, double-blind cross-over study. J Intern Med 229: 535-538, 1991.
37. Tsagadopoulos D, Antonakoudis H, Makris T, et al. Effect of anti-hypertensive treatment on lipids and fibrinogen: Greek multicentre study of cilazapril. Cardiology 87: 524-528, 1996.
38. Laakso M, Karjalaainen L, Lempiainen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 28: 392-396, 1996.
39. Moan A, Hoieggen A, Seljeflot I, Risanger T, Amesen H, Kjeldsen SE. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 14: 1083-1097, 1996.
40. Grassi G, Seravalle G, Dell'Oro R, et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 21: 1761-1769, 2003.
41. Furuhashi M, Ura N, Takizawa H, et al. Blockade of the rennin angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22: 1977-1982, 2004.
42. Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 27: 293-299, 2004.
43. De Vinuesa SG, Giocoechea M, Kanter J, et al. Insulin resistance, inflammatory biomarkers and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 17: S206-S212, 2006.
44. Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med 118: 529-539, 1993.
45. Harper R, Ennis CN, Heaney AP, et al. A comparison of the effects of low- and conventionaldose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 38: 853-859, 1995.
46. Wofford MR, King DS, Harrel TK. Drug-induced metabolic syndrome. J Clin Hypertens 8: 114-119, 2006.
47. Rayner BL, Trinder YA, Baines D, Isaacs S, Opie LH. Effect of losartan versus candesartan on uric acid, renal function and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 19: 208-213, 2006.
48. Khder Y, Bray des, Boscs L, El Ghawi R, et al. Calcium antagonists and thiazide diuretics have opposite effects on blood rheology and radial artery compliance in arterial hypertension: a randomized double-blind study. Fundam Clin Pharmacol 12: 457-462, 1998.